Phase I non-myeloblative trial with 90Y-humanized MN-14 (anti-CEA) [carcinoembryonic antigen] antibody [labetuzumab Y-90] for relapsed or refractory small cell lung cancer (SCLC).

Trial Profile

Phase I non-myeloblative trial with 90Y-humanized MN-14 (anti-CEA) [carcinoembryonic antigen] antibody [labetuzumab Y-90] for relapsed or refractory small cell lung cancer (SCLC).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2009

At a glance

  • Drugs Labetuzumab Y-90 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top